CTOs on the Move

CinRx Pharma

www.cinrx.com

 
CinRx Pharma is a multi-asset biotech company focusing on advancing novel therapeutics that address large unmet medical needs.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.cinrx.com
  • 5375 Medpace Way
    Cincinnati, AK USA 45227
  • Phone: 844.531.1834

Executives

Name Title Contact Details

Funding

CinRx Pharma raised $10M on 11/28/2017

Similar Companies

Garuda Therapeutics

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.

Mohawk Shared Services

Mohawk Shared Services is a Burlington, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prolong Pharmaceuticals

Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.